Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fan Jin

Showing results (391-400 of 397) with videos related to

Pageof 40
Sort By:
You have reached the last page of results.This site can display upto 397 results.
Cancer Research Communications|February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 StudyMariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Physical Biology|January 19, 2021
Roadmap on emerging concepts in the physical biology of bacterial biofilms: from surface sensing to community formationGerard C L Wong, Jyot D Antani, Pushkar P Lele, et al.
Pageof 40

Showing results (391-400 of 397) with videos related to

Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 397 results.
Cancer Research Communications|February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 StudyMariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Physical Biology|January 19, 2021
Roadmap on emerging concepts in the physical biology of bacterial biofilms: from surface sensing to community formationGerard C L Wong, Jyot D Antani, Pushkar P Lele, et al.
Pageof 40